Madrigal Pharmaceuticals, Inc. (MDGL)

Last Price:  

Company Description

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-? agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-? agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-202.24M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 7.23
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -64.30%
Return on Assets (Trailing 12 Months) -56.71%
Current Ratio (Most Recent Fiscal Quarter) 6.13
Quick Ratio (Most Recent Fiscal Quarter) 6.13
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $15.52
Earnings per Share (Most Recent Fiscal Quarter) $-3.82
Earnings per Share (Most Recent Fiscal Year) $-13.09
Diluted Earnings per Share (Trailing 12 Months) $-13.09
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 16.02M
Free Float 9.31M
Market Capitalization $1.80B
Average Volume (Last 20 Days) 0.18M
Beta (Past 60 Months) 0.99
Percentage Held By Insiders (Latest Annual Proxy Report) 41.89%
Percentage Held By Institutions (Latest 13F Reports) 78.22%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%